GlassScriptPhysician profile
Benjamin Lee Kitchens
NPI 1841637477
$177,032.95
in general payments reported to CMS, 2019-2025
59 companies · $84K in 2025
The $84K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $1,100 · 2021: $853 · 2022: $800 · 2023: $25K · 2024: $64K · 2025: $84K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $119K · Consulting Fee: $23K · Travel and Lodging: $22K · Food and Beverage: $8,813 · Education: $16.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $119,295.50 |
| Consulting Fee | $23,022.25 |
| Travel and Lodging | $22,252.70 |
| Food and Beverage | $8,812.63 |
| Education | $16.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $65,590.72 | 2019-2025 | Vyloy, Padcev, Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $28,414.54 | 2021-2025 | Fruzaqla |
| Incyte Corporation | $25,425.94 | 2020-2025 | Zynyz, Monjuvi, Pemazyre |
| Ipsen Biopharmaceuticals, INC | $18,373.19 | 2023-2024 | Onivyde, Somatuline Depot |
| Astrazeneca Pharmaceuticals LP | $17,634.42 | 2019-2025 | Imfinzi, Imjudo, Lynparza |
| Jazz Pharmaceuticals INC. | $14,367.32 | 2023-2025 | Zepzelca |
| Genentech USA, INC. | $1,434.18 | 2020-2024 | |
| Abbvie INC. | $618.21 | 2022-2025 | |
| Janssen Biotech, INC. | $554.51 | 2019-2025 | Darzalex, Imbruvica, Tecvayli |
| Merck Sharp & Dohme LLC | $522.76 | 2019-2025 | Keytruda, Welireg |
| Regeneron Healthcare Solutions, INC. | $293.17 | 2021-2025 | Libtayo |
| Eisai INC. | $290.99 | 2023-2025 | |
| Pfizer INC. | $264.85 | 2019-2025 | |
| Astellas Pharma Global Development | $216.00 | 2025 | Vyloy |
| Seagen INC. | $214.76 | 2020-2023 | Tukysa, Adcetris |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Kitchens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.